News

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

he NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for autoimmune diseases, today recognized its co-founders, Dr. Josep Bassaganya-Riera and Dr. Raquel Hontecillas, and scientific director Dr. Andrew Leber for their leadership in the discovery and development of NX-13 that enabled today’s acquisition of Landos Biopharma, Inc. (“Landos”) by AbbVie, Inc. (NYSE: ABBV) (“AbbVie”). Dr. Bassaganya-Riera founded Landos in 2017 and led the Company’s subsequent growth from inception through multiple rounds of private funding, a successful IPO, growth as a NASDAQ-listed biopharma company with market capitalization in excess of $625 million, 7 INDs and 17 therapeutic development programs, including the successful clinical development of NX-13 and omilancor for the treatment of ulcerative colitis (UC) and potentially other autoimmune diseases.

“NIMML’s TITAN-X Precision Medicine platform and its advanced A.I. and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13. The acquisition of Landos and NX-13 by AbbVie, the maker of several blockbuster IBD drugs, validates the value of the TITAN-X platform to discover a portfolio of first and best in class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases with high unmet patient needs,” said Dr. Bassaganya-Riera, President and CEO of NIMML. “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades. This transaction is a tremendous validation of the work and dedication of the entire NIMML team and the robustness of the TITAN-X drug discovery platform in strengthening a global pipeline of I&I therapeutics.”

Drs. Bassaganya-Riera, Hontecillas and Leber were the sole inventors of NX-13 and first designed the small molecule to target NLRX1 in 2017. After discovery, the three accelerated the de-risking of NX-13 preclinically, including translational target engagement and multiple mouse models (published in the Journal of Immunology), and a novel proprietary pig model of IBD previously developed by Drs. Bassaganya-Riera and Hontecillas, following the same path that was used to develop omilancor. With this robust data package, the team opened INDs for NX-13 in UC and Crohn’s disease (CD) and successfully completed a Phase I study in normal healthy volunteers. Prior to their departure from Landos, Drs. Bassaganya-Riera, Hontecillas and Leber designed, initiated, and conducted a Phase Ib study in UC patients for NX-13, which has yielded the only clinical efficacy results released to the public to date.

In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines. NImmune is led by Dr. Bassaganya-Riera as the Chief Executive Officer, Dr. Hontecillas as the Chief Scientific Officer, and Dr. Leber as the Chief Development Officer. In May 2023, the NIMML Institute executed a precision medicine research collaboration with NImmune to develop the LANCL2 portfolio of immunoregulatory therapeutics, including omilancor and NIM-1324, oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway. Omilancor is currently in a global registration-directed Phase 3 program to treat UC. Final and complete Phase 2 data published on October 2023 at ACG showed that once daily omilancor induced a best-in-class remission rate of 30.4% in UC patients versus 3.7% in the placebo arm (P=0.01) with an unrivaled safety profile. NIM-1324 is anticipated to begin a Phase 2 program in Systemic Lupus Erythematosus (SLE) patients during 2H’24. NIM-1324 is also in clinical development for Rheumatoid Arthritis (RA) and other systemic autoimmune diseases. Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

“Today’s transaction reinforces the novel immunoregulatory target discovery programs of the NIMML Institute, including LANCL2 and NLRX1, as well as the strong efficacy and safety profile of the innovative therapeutics we continue to develop at NImmune,” said Dr. Hontecillas, Co-Director and Chief Scientific Officer at NIMML. “The acquisition of NX-13 by one of the world’s leading biopharma companies signals continued momentum behind the important work we are doing to advance the development of effective treatments that can safely address the significant unmet clinical needs of millions of patients living with autoimmune diseases.”

Crucial to the development of NX-13, the NIMML team first characterized the key role of NLRX1 – a mitochondria-associated receptor involved in down-regulating inflammation – in the protection from IBD. NLRX1 modulates epithelial cell metabolism and the gut microbiota, which was demonstrated through seminal publications of immunology studies conducted by Dr. Bassaganya-Riera’s team, finding deficiency of NLRX1 worsens inflammatory responses in both CD4+ T cells and epithelial cells and shifts the metabolic preferences of cells. The NIMML team identified transdisciplinary mechanisms of NLRX1 anti-inflammatory effects whereby the regulation of lactate metabolism by NLRX1 aids in the prevention of effector T cell responses and the regulation of glutamine metabolism aids in the maintenance of epithelial barrier integrity. These immunometabolic findings laid the groundwork for Dr. Bassaganya-Riera’s team’s clinical development of NX-13 as a novel NLRX1 agonist oral therapy for the treatment of UC.

Read more here.

Recent News

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.

04/15/2024

Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them